NEW YORK (GenomeWeb) – 23andMe today announced an agreement with drug developer Reset Therapeutics to study the genetics of the circadian clock.

The goal of the collaboration is to develop drug targets for therapeutics that will restore the body's 24-hour physiological rhythms, Reset said in a statement.

Through this collaboration, 23andMe will provide Reset scientists with de-identified, aggregated data from more than 650,000 customers who have consented for their genomic information to be a part of scientific research.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.